Otenabant

DB11745InvestigationalSmall molecule

Otenabant has been investigated for the treatment of Obesity.

Mechanism: Pre-clinical and clinical trial data suggest that CB-1 antagonists may have favorable effects on glucose metabolism in patients with type 2 diabetes and may also be an effective therapy for the treatment of obesity.
Curator reviewed
Formula / weight: C₂₅H₂₅Cl₂N₇O · 510.42 g/mol (avg)
Code names: CP-945,598 · CP-945598-01

Resolves to

Compound

Structure

InChIKeyUNAZAADNBYXMIV-UHFFFAOYSA-NSMILESCCNC1(CCN(CC1)C1=C2N=C(N(C2=NC=N1)C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl)C(N)=O

Targets

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Otenabant, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.